Literature DB >> 1984227

Stability of immunoreactive beta-core fragment of hCG.

S F de Medeiros1, F Amato, R J Norman.   

Abstract

The beta core fragment of hCG (beta C-hCG) accounts for a large proportion of hCG immunoreactivity in the urine of pregnant women. It is often increased in the urine of patients with gynecologic tumors and may become an important diagnostic tool in early pregnancy and cancers. Despite the importance of beta C-hCG, little is known about its stability in urine under conditions of differing pH and temperature. This study examined the effect of repeated freeze-thaw cycles; storage at room temperature, 4C, and -20 C over several months; and the effect of alteration of urine pH. The two specific immunoassays for beta C-hCG used do not significantly cross-react with intact hCG or the free alpha subunit. Despite different cross-reactivities of the antibodies to the free beta subunit and higher immunoactivity when the radioimmunoassay was used, there was excellent correlation between the two assays in pregnancy urine. This suggests that there is little free beta subunit in urine from pregnant women. In addition, this study evaluated the stability of intact hCG and beta-hCG under identical conditions. No alterations in their immunoactivities were found under most conditions of storage. It is concluded that, for clinical purposes, beta C-hCG as well as intact hCG and free beta subunit are very stable molecules.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984227

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance.

Authors:  Lisa S Kelly; Steven Birken; David Puett
Journal:  Mol Cell Endocrinol       Date:  2006-11-01       Impact factor: 4.102

2.  Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.

Authors:  O el-Ahmady; A B Halim; O Mansour; T Salman; A G el-Din; R P Walker
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.